electroCore

electroCore, Inc. (Nasdaq: ECOR) is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005[1] by JP Errico Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The current chief executive officer is Daniel S. Goldberger.[2] electroCore[3] has one product called gammaCore,[4][5] a non-invasive, commercially available product that uses vagus nerve stimulation.[6]

This article is about a medical technology company. For music genres, see Electronicore.

On March 27, 2020, electroCore announced a common stock purchase agreement of up to $25 million with Chicago-based institutional investor Lincoln Park Capital Fund, LLC.[7]

Products

gammaCore Sapphire CV

In July 2020, the FDA gave an emergency COVID-19 authorization for gammaCore Sapphire CV, a vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma.[8]

gollark: It's not strictly necessary, but it would be nice if any reactor design would work on any other NuclearCraft installation of the same version.
gollark: They could be added if the mods were installed, *but* then half the reactor designs won't work if you don't have them.
gollark: Trouble is that then these mods would probably be required as dependencies.
gollark: Clearly the answer is to multiply all cooling by 86x10^18.
gollark: MY GLOWSTONE SPAM!

References
  1. "Company Overview of electroCore, Inc". www.bloomberg.com. Retrieved 2019-03-06.
  2. "Nerve stimulation device maker electroCore goes public with $78M IPO | FierceBiotech". www.fiercebiotech.com. Retrieved 2019-03-06.
  3. "This hand-held device is approved to treat cluster headaches". NBC News. Retrieved 2019-03-06.
  4. "ElectroCore wins cluster headache FDA 510(k) indication for GammaCore". MassDevice. 2018-11-28. Retrieved 2019-03-06.
  5. "Nerve Stimulator Approved for Cluster Headache". Pain News Network. Retrieved 2019-03-06.
  6. "Term Sheet -- Friday, June 22". Fortune. Retrieved 2019-03-06.
  7. "BRIEF-electroCore Announces Common Stock Purchase Agreement For Up To $25 Mln With Lincoln Park Capital". Reuters. 2020-03-27. Retrieved 2020-03-31.
  8. electroCore (2020-07-13). "electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients". GlobeNewswire News Room. Retrieved 2020-07-15.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.